- 作者：Kitty Pavlakis ; Thomas Vrekoussis ; Anna Tsipoura ; Artemis Tsenga ; Petroula Arapantoni-Dadioti ; Theofani Gavresea ; Irini Messini ; Vassilis Barbounis
- 关键词：Breast cancer ; Ki-67 ; Immunohistochemistry
- 刊名：The Breast
- 出版年：2012
- 出版时间：August, 2012
- 年：2012
- 卷：21
- 期：4
- 页码：529-533
- 全文大小：202 K
Aim
To determine the degree of inter-observer variability in defining the percentage of Ki-67 immunohistochemical expression in breast carcinoma cases and to investigate the validity of using the cut-point of 14 % for the administration of adjuvant treatment in luminal B (Her2 negative) carcinomas.Materials and methods
99 ER, PR positive, Her2 negative breast carcinomas were consecutively selected from the Pathology files of ¡°IASO¡± Women's Hospital. Ki-67 immunostaining was evaluated by four pathologists from four different institutions.
Results
Concerning the whole study group, the inter-observer agreement was substantial. Subgroup analysis upon the cases were at least one observer evaluated Ki-67 as being less than 14 % showed that the inter-observer agreement was reduced to fair. Further analysis revealed that both below and above the clinicopathological limit of 14 % , stands a ¡°grey zone¡± of about ¡À7 % , in which inter-observer agreement is weak.
Conclusion
The administration of cytotoxic therapy in ER, PR positive, Her2 negative breast carcinomas featuring a Ki-67 labeling index of around 14, should be considered with caution. Probably decision-making should also take under consideration the whole morphological and biological profile of each tumor.